OrbiMed’s Haemonetics HAE Stock Holding History

OrbiMed’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-852,000	Closed	-$94.6M	–	166
2021 Q1	$94.6M	Buy	+852,000	New	+$105M	0.88%	34

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

OrbiMed's HAE Position: Q2 2021 in Review

OrbiMed sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 852,000 shares — an estimated $94.6M sold.

OrbiMed first reported a position in HAE in Q1 2021 and held it in 1 quarter. The position peaked at $94.6M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

OrbiMed reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
OrbiMed sold 852,000 Haemonetics shares in Q2 2021, an estimated $94.6M.
OrbiMed first reported a position in Haemonetics in Q1 2021 and held it in 1 quarter.
OrbiMed's Haemonetics position peaked at $94.6M in Q1 2021.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.